SCHEMBL3427338

SCHEMBL3427338

CS(=O)(=O)Nc1cccc(CCC(=O)O)c1OCC1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 1/20 0.40
▸ NR3C1 P04150 6/20 0.40
▸ THRA P10827 2/20 0.40
▸ THRB P10828 2/20 0.40
▸ MRGPRX1 Q96LB2 1/20 0.40
▸ PDE4A P27815 1/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ PDE4C Q08493 1/20 0.39
▸ PDE4D Q08499 1/20 0.39
▸ PTGER4 P35408 2/20 0.38
▸ PTGER3 P43115 2/20 0.38
▸ PTGER2 P43116 2/20 0.38
▸ PTGER1 P34995 1/20 0.38
▸ CXCR5 P32302 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ FFAR1 O14842 1/20 0.38
▸ CYP19A1 P11511 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3430522 0.82 LMNA (0.43) MTNR1ANR3C1PTGER4PTGER3PTGER2
SCHEMBL3403005 0.81 NR3C1 (0.43) NR3C1THRATHRBPTGER4PTGER3
SCHEMBL3405503 0.79 NR3C1 (0.42) NR3C1PTGER4PTGER3PTGER2PTGER1
SCHEMBL3409167 0.77 THRA (0.47) THRATHRBPDE4DPTGER4PTGER3
SCHEMBL7725082 0.72 THRA (0.53) NR3C1THRATHRBKMT2AFFAR1
SCHEMBL31661793 0.71 THRA (0.67) THRATHRBPTGER4PTGER3PTGER2
SCHEMBL3055708 0.71 THRA (0.67) THRATHRBPTGER4PTGER3PTGER2
SCHEMBL14798300 0.71 MRGPRX1 (0.57) MRGPRX1PDE4APDE4BPDE4CPDE4D
SCHEMBL5112565 0.67 THRA (0.63) NR3C1THRATHRBFFAR1
SCHEMBL29723405 0.67 CYP19A1 (0.56) MRGPRX1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487121-B2 Chromane derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2013-07-16 — — US disclosed
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2010-12-09 — — US disclosed
EP-2254879-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2010-12-01 — — EP disclosed
WO-2009084034-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS, S. A. (CH) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS TRPV3, TRPV2, TRPV1 MTNR1A 187/4885NR3C1 403/4885THRA 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback